TY - JOUR
T1 - Imaging practice in low-grade gliomas among European specialized centers and proposal for a minimum core of imaging
AU - Freyschlag, Christian F.
AU - Krieg, Sandro M.
AU - Kerschbaumer, Johannes
AU - Pinggera, Daniel
AU - Forster, Marie-Therese
AU - Cordier, Dominik
AU - Rossi, Marco
AU - Miceli, Gabriele
AU - Roux, Alexandre
AU - Reyes, Andrés
AU - Sarubbo, Silvio
AU - Smits, Anja
AU - Sierpowska, Joanna
AU - Robe, Pierre A.
AU - Rutten, Geert-Jan
AU - Santarius, Thomas
AU - Matys, Tomasz
AU - Zanello, Marc
AU - Almairac, Fabien
AU - Mondot, Lydiane
AU - Jakola, Asgeir S.
AU - Zetterling, Maria
AU - Rofes, Adrià
AU - von Campe, Gord
AU - Guillevin, Remy
AU - Bagatto, Daniele
AU - Lubrano, Vincent
AU - Rapp, Marion
AU - Goodden, John
AU - de Witt Hamer, Philip C.
AU - Pallud, Johan
AU - Bello, Lorenzo
AU - Thomé, Claudius
AU - Duffau, Hugues
AU - Mandonnet, Emmanuel
PY - 2018
Y1 - 2018
N2 - Objective: Imaging studies in diffuse low-grade gliomas (DLGG) vary across centers. In order to establish a minimal core of imaging necessary for further investigations and clinical trials in the field of DLGG, we aimed to establish the status quo within specialized European centers. Methods: An online survey composed of 46 items was sent out to members of the European Low-Grade Glioma Network, the European Association of Neurosurgical Societies, the German Society of Neurosurgery and the Austrian Society of Neurosurgery. Results: A total of 128 fully completed surveys were received and analyzed. Most centers (n = 96, 75%) were academic and half of the centers (n = 64, 50%) adhered to a dedicated treatment program for DLGG. There were national differences regarding the sequences enclosed in MRI imaging and use of PET, however most included T1 (without and with contrast, 100%), T2 (100%) and TIRM or FLAIR (20, 98%). DWI is performed by 80% of centers and 61% of centers regularly performed PWI. Conclusion: A minimal core of imaging composed of T1 (w/wo contrast), T2, TIRM/FLAIR, PWI and DWI could be identified. All morphologic images should be obtained in a slice thickness of ≤ 3 mm. No common standard could be obtained regarding advanced MRI protocols and PET. Importance of the study: We believe that our study makes a significant contribution to the literature because we were able to determine similarities in numerous aspects of LGG imaging. Using the proposed “minimal core of imaging” in clinical routine will facilitate future cooperative studies.
AB - Objective: Imaging studies in diffuse low-grade gliomas (DLGG) vary across centers. In order to establish a minimal core of imaging necessary for further investigations and clinical trials in the field of DLGG, we aimed to establish the status quo within specialized European centers. Methods: An online survey composed of 46 items was sent out to members of the European Low-Grade Glioma Network, the European Association of Neurosurgical Societies, the German Society of Neurosurgery and the Austrian Society of Neurosurgery. Results: A total of 128 fully completed surveys were received and analyzed. Most centers (n = 96, 75%) were academic and half of the centers (n = 64, 50%) adhered to a dedicated treatment program for DLGG. There were national differences regarding the sequences enclosed in MRI imaging and use of PET, however most included T1 (without and with contrast, 100%), T2 (100%) and TIRM or FLAIR (20, 98%). DWI is performed by 80% of centers and 61% of centers regularly performed PWI. Conclusion: A minimal core of imaging composed of T1 (w/wo contrast), T2, TIRM/FLAIR, PWI and DWI could be identified. All morphologic images should be obtained in a slice thickness of ≤ 3 mm. No common standard could be obtained regarding advanced MRI protocols and PET. Importance of the study: We believe that our study makes a significant contribution to the literature because we were able to determine similarities in numerous aspects of LGG imaging. Using the proposed “minimal core of imaging” in clinical routine will facilitate future cooperative studies.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85049666933&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29992433
U2 - https://doi.org/10.1007/s11060-018-2916-3
DO - https://doi.org/10.1007/s11060-018-2916-3
M3 - Article
C2 - 29992433
SN - 0167-594X
VL - 139
SP - 699
EP - 711
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
IS - 3
ER -